{"title":"达到指南为基础的低密度脂蛋白胆固醇目标水平对冠状动脉疾病经导管主动脉瓣植入术患者死亡率的影响","authors":"Ö. Demir, F. Levent","doi":"10.18621/eurj.1341976","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of this retrospective study was to evaluate the effects of bringing low-density lipoprotein cholesterol (LDL-C) values to levels in line with guideline recommendations on long-term mortality in patients with a known history of coronary artery disease (CAD), undergoing transcatheter aortic valve implantation (TAVI), and long-term pre-treatment with statins. \nMethods: This is a retrospective and observational study of patients undergoing TAVI at a tertiary heart center with a history of CAD and long-term statin therapy. Ninety-nine patients were included in the study. The relationship between LDL-C levels in accordance with the guidelines and 5-year mortality was determined by regression analysis. \nResults: When the study population was divided into 2 groups with and without 5-year mortality, LDL-C values were found to be significantly higher in the mortality group (120 mg/dL vs. 93.9 mg/dL, p < 0.001). Parameters associated with the development of 5-year mortality were evaluated with univariate and multivariate logistic regression analysis. LDL-C ≥ 100 mg/dL (OR: 6.59, 95% CI: 2.17-20.01) and LDL-C ≥ 70 mg/dL (OR:3.88, 95% CI: 1.16-12.93) parameters were determined as independent predictors of mortality independent of other parameters. \nConclusions: The most important result obtained in this study is that achieving the LDL-C level targets specified in the guidelines significantly reduces the in-hospital and 5-year mortality rates in patients with a previous history of CAD and statin use and undergoing TAVI. Although all patients included in the study used statins, the mortality rate was significantly higher in patients who did not reach the target LDL-C value.","PeriodicalId":22571,"journal":{"name":"The European Research Journal","volume":"51 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of achieving guideline-based target low-density lipoprotein cholesterol levels on mortality in transcatheter aortic valve implantation patients with coronary artery disease\",\"authors\":\"Ö. Demir, F. Levent\",\"doi\":\"10.18621/eurj.1341976\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: The aim of this retrospective study was to evaluate the effects of bringing low-density lipoprotein cholesterol (LDL-C) values to levels in line with guideline recommendations on long-term mortality in patients with a known history of coronary artery disease (CAD), undergoing transcatheter aortic valve implantation (TAVI), and long-term pre-treatment with statins. \\nMethods: This is a retrospective and observational study of patients undergoing TAVI at a tertiary heart center with a history of CAD and long-term statin therapy. Ninety-nine patients were included in the study. The relationship between LDL-C levels in accordance with the guidelines and 5-year mortality was determined by regression analysis. \\nResults: When the study population was divided into 2 groups with and without 5-year mortality, LDL-C values were found to be significantly higher in the mortality group (120 mg/dL vs. 93.9 mg/dL, p < 0.001). Parameters associated with the development of 5-year mortality were evaluated with univariate and multivariate logistic regression analysis. LDL-C ≥ 100 mg/dL (OR: 6.59, 95% CI: 2.17-20.01) and LDL-C ≥ 70 mg/dL (OR:3.88, 95% CI: 1.16-12.93) parameters were determined as independent predictors of mortality independent of other parameters. \\nConclusions: The most important result obtained in this study is that achieving the LDL-C level targets specified in the guidelines significantly reduces the in-hospital and 5-year mortality rates in patients with a previous history of CAD and statin use and undergoing TAVI. Although all patients included in the study used statins, the mortality rate was significantly higher in patients who did not reach the target LDL-C value.\",\"PeriodicalId\":22571,\"journal\":{\"name\":\"The European Research Journal\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The European Research Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18621/eurj.1341976\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European Research Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18621/eurj.1341976","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:本回顾性研究的目的是评估将低密度脂蛋白胆固醇(LDL-C)值降至符合指南建议的水平对已知冠状动脉疾病(CAD)病史、接受经导管主动脉瓣置入术(TAVI)和长期他汀类药物预处理的患者的长期死亡率的影响。方法:这是一项回顾性和观察性研究,在三级心脏中心接受TAVI的患者有CAD病史和长期他汀类药物治疗。99名患者参与了这项研究。通过回归分析确定指南中LDL-C水平与5年死亡率之间的关系。结果:将研究人群分为有5年死亡率和无5年死亡率两组时,发现死亡率组LDL-C值显著高于死亡率组(120 mg/dL vs. 93.9 mg/dL, p < 0.001)。采用单因素和多因素logistic回归分析评估与5年死亡率发展相关的参数。LDL-C≥100 mg/dL (OR: 6.59, 95% CI: 2.17-20.01)和LDL-C≥70 mg/dL (OR:3.88, 95% CI: 1.16-12.93)参数被确定为独立于其他参数的死亡率预测因子。结论:本研究获得的最重要的结果是,达到指南规定的LDL-C水平目标可显著降低有CAD和他汀类药物使用史并接受TAVI的患者的住院死亡率和5年死亡率。尽管纳入研究的所有患者均使用他汀类药物,但未达到LDL-C目标值的患者死亡率明显较高。
The effect of achieving guideline-based target low-density lipoprotein cholesterol levels on mortality in transcatheter aortic valve implantation patients with coronary artery disease
Objectives: The aim of this retrospective study was to evaluate the effects of bringing low-density lipoprotein cholesterol (LDL-C) values to levels in line with guideline recommendations on long-term mortality in patients with a known history of coronary artery disease (CAD), undergoing transcatheter aortic valve implantation (TAVI), and long-term pre-treatment with statins.
Methods: This is a retrospective and observational study of patients undergoing TAVI at a tertiary heart center with a history of CAD and long-term statin therapy. Ninety-nine patients were included in the study. The relationship between LDL-C levels in accordance with the guidelines and 5-year mortality was determined by regression analysis.
Results: When the study population was divided into 2 groups with and without 5-year mortality, LDL-C values were found to be significantly higher in the mortality group (120 mg/dL vs. 93.9 mg/dL, p < 0.001). Parameters associated with the development of 5-year mortality were evaluated with univariate and multivariate logistic regression analysis. LDL-C ≥ 100 mg/dL (OR: 6.59, 95% CI: 2.17-20.01) and LDL-C ≥ 70 mg/dL (OR:3.88, 95% CI: 1.16-12.93) parameters were determined as independent predictors of mortality independent of other parameters.
Conclusions: The most important result obtained in this study is that achieving the LDL-C level targets specified in the guidelines significantly reduces the in-hospital and 5-year mortality rates in patients with a previous history of CAD and statin use and undergoing TAVI. Although all patients included in the study used statins, the mortality rate was significantly higher in patients who did not reach the target LDL-C value.